Latrepirdine
- Generic Name
- Latrepirdine
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3
- CAS Number
- 3613-73-8
- Unique Ingredient Identifier
- OD9237K1Z6
- Background
Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.
BioXcel Therapeutics Advances Phase 3 Trials of BXCL501 for Agitation
• BioXcel Therapeutics has randomized the first patient in the SERENITY At-Home trial, evaluating BXCL501 for acute agitation associated with bipolar disorders or schizophrenia.
• The company received FDA feedback on the protocol for the TRANQUILITY In-Care trial, which studies BXCL501 for agitation related to Alzheimer’s dementia.
• These Phase 3 trials address a significant unmet need, with an estimated 140 million annual acute agitation episodes associated with these conditions.
• BXCL501, already approved as IGALMI™ for agitation under supervision, seeks expanded use for at-home treatment and a new indication for Alzheimer's-related agitation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath